[vc_row][vc_column][vc_column_text]4 Million Covered Lives Provided Access to MarginProbe
Caesarea, Israel, March 12, 2012. Dilon announced today that Clalit, Israel’s largest HMO, with a network of 8 surgical centers and 4 million insured, has informed Dilon that it has approved the MarginProbe System for use throughout the Clalit network. The MarginProbe System provides surgeons the ability to detect microscopic cancer
intraoperatively, allowing removal of all the cancer in a single surgery, dramatically reducing the need for repeat surgeries in patients undergoing breast cancer lumpectomy surgery.
“This decision by the country’s largest HMO is another step in the successful implementation of our marketing strategy for MarginProbe,” said Dan Levangie, CEO of Dilon. “We
intend to bring the benefits of the MarginProbe System to all breast cancer surgery patients in every territory in which we operate. This decision by Clalit is an important step in that
Between 20-40% of patients having a lumpectomy for breast cancer will require more than one surgery to remove all the cancer. Results of a multicenter clinical study of the MarginProbe System in Germany, recently presented at the Forum for Operative Gynecology in Berlin, demonstrated that use of MarginProbe System led to more than a 50% reduction in unnecessary repeat surgeries for lumpectomy patients.
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic
applications. The MarginProbe System is Dune’s first commercial product and is commercially available in Israel and Europe. The MarginProbe device is an investigational device in the U.S. Dilon Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit www.dilon.com.[/vc_column_text][/vc_column][/vc_row]